Oliver Zolk

6.4k total citations
109 papers, 4.6k citations indexed

About

Oliver Zolk is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Oncology. According to data from OpenAlex, Oliver Zolk has authored 109 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Molecular Biology, 35 papers in Cardiology and Cardiovascular Medicine and 34 papers in Oncology. Recurrent topics in Oliver Zolk's work include Drug Transport and Resistance Mechanisms (23 papers), Receptor Mechanisms and Signaling (16 papers) and Renin-Angiotensin System Studies (13 papers). Oliver Zolk is often cited by papers focused on Drug Transport and Resistance Mechanisms (23 papers), Receptor Mechanisms and Signaling (16 papers) and Renin-Angiotensin System Studies (13 papers). Oliver Zolk collaborates with scholars based in Germany, United States and Netherlands. Oliver Zolk's co-authors include Martin F. Fromm, Michael Böhm, Jörg König, Thomas Eschenhagen, Antonio Sarikas, Georg Nickenig, Thorsten Langer, Renke Maas, Jenni E. Keskitalo and Benjamin Mayer and has published in prestigious journals such as Circulation, Blood and PLoS ONE.

In The Last Decade

Oliver Zolk

105 papers receiving 4.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Oliver Zolk Germany	42	1.5k	1.4k	1.4k	687	552	109	4.6k
Gillian Smith United Kingdom	44	2.1k 1.4×	1.5k 1.0×	1.9k 1.4×	331 0.5×	466 0.8×	127	7.1k
Leszek Wojnowski Germany	39	2.5k 1.7×	1.8k 1.3×	589 0.4×	788 1.1×	384 0.7×	93	6.1k
Agnes Jager Netherlands	46	1.4k 1.0×	2.5k 1.7×	777 0.6×	208 0.3×	658 1.2×	227	7.0k
Takashi Izumi Japan	41	1.6k 1.1×	1.2k 0.9×	740 0.5×	341 0.5×	508 0.9×	267	7.1k
Marie‐Anne Loriot France	44	1.3k 0.9×	1.3k 0.9×	244 0.2×	743 1.1×	452 0.8×	159	5.8k
Markus Grube Germany	34	785 0.5×	1.7k 1.2×	367 0.3×	810 1.2×	315 0.6×	71	3.3k
John R. Sedor United States	44	2.2k 1.5×	343 0.2×	654 0.5×	347 0.5×	540 1.0×	150	6.2k
Jun Wang China	40	2.2k 1.5×	1.2k 0.8×	326 0.2×	270 0.4×	588 1.1×	269	6.3k
William Lewis United States	44	2.4k 1.6×	358 0.3×	1.6k 1.2×	231 0.3×	400 0.7×	111	6.8k
Liberato Berrino Italy	46	2.0k 1.3×	1.0k 0.7×	1.7k 1.2×	124 0.2×	577 1.0×	165	6.5k

Countries citing papers authored by Oliver Zolk

Since Specialization

Citations

This map shows the geographic impact of Oliver Zolk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Zolk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Zolk more than expected).

Fields of papers citing papers by Oliver Zolk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver Zolk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Zolk. The network helps show where Oliver Zolk may publish in the future.

Co-authorship network of co-authors of Oliver Zolk

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Zolk. A scholar is included among the top collaborators of Oliver Zolk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Zolk. Oliver Zolk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baumann, Sybille, Isabella Gashaw, Stefan Klein, et al.. (2025). Safety, Tolerability, and Pharmacokinetics of Filapixant, a Highly Selective P2X3 Receptor Antagonist, in an Ascending-Single-Dose First-in-Human Study. Pharmaceuticals. 18(5). 758–758. 1 indexed citations

Broer, Linda, Oliver Zolk, Marieke J. H. Coenen, et al.. (2025). The influence of genetic variation on late effects in childhood cancer survivors: An updated systematic review. Critical Reviews in Oncology/Hematology. 216. 104977–104977.

Peter, Jens‐Uwe, et al.. (2025). Age and Sex Differences in Adverse Events Associated With Antipsychotics: An Analysis of the FDA Adverse Events Database. International Journal of Geriatric Psychiatry. 40(8). e70142–e70142. 1 indexed citations

Peter, Jens‐Uwe, Michael Schneider, Martin Heinze, et al.. (2024). Age and sex differences in outpatient antipsychotic prescriptions for schizophrenia: a claims data study. European Archives of Psychiatry and Clinical Neuroscience. 275(5). 1403–1417. 3 indexed citations

Joos, Stefanie, Yvonne Kaußner, Uwe Malzahn, et al.. (2024). Feasibility, safety and effectiveness of prednisolone and vitamin B1, B6, and B12 in patients with post-COVID-19-syndrome (PreVitaCOV) – protocol of a randomised, double-blind, placebo-controlled multicentre trial in primary care (phase IIIb). BMC Infectious Diseases. 24(1). 56–56. 5 indexed citations

Friedrich, Christian, Dave Singh, Stefan Klein, et al.. (2024). Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending‐dose study in healthy young men. British Journal of Clinical Pharmacology. 90(8). 2004–2018. 1 indexed citations

Grebinyk, Sergii, Svitlana Prylutska, Uwe Ritter, et al.. (2023). Silent Death by Sound: C60 Fullerene Sonodynamic Treatment of Cancer Cells. International Journal of Molecular Sciences. 24(2). 1020–1020. 9 indexed citations

Neudorf, Ulrich, Christian Apitz, Inga Voges, et al.. (2023). Kardiovaskuläre Toxizität der Therapie onkologischer Erkrankungen bei Kindern und Jugendlichen. Monatsschrift Kinderheilkunde. 172(S1). 14–42.

Verlouw, Joost, Eva Clemens, Oliver Zolk, et al.. (2021). A comparison of genotyping arrays. European Journal of Human Genetics. 29(11). 1611–1624. 51 indexed citations

10.

Zolk, Oliver, Norbert Graf, Thorsten Simon, et al.. (2021). Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study. JMIR Research Protocols. 11(2). e27898–e27898. 3 indexed citations

11.

Zolk, Oliver, Timo Greiner, Michael Schneider, et al.. (2021). Antipsychotic drug treatment of schizophrenia in later life: Results from the European cross-sectional AMSP study. The World Journal of Biological Psychiatry. 23(5). 374–386. 6 indexed citations

12.

Zolk, Oliver, Rebecca Halbgebauer, Britta Höchsmann, et al.. (2020). Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity. Blood. 137(4). 443–455. 65 indexed citations

13.

Zolk, Oliver, Susanne Häfner, & Christoph Q. Schmidt. (2020). COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments. Naunyn-Schmiedeberg s Archives of Pharmacology. 393(7). 1131–1135. 18 indexed citations

14.

Oosterom, Natanja, Oliver Zolk, Saskia M.F. Pluijm, et al.. (2018). The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia. Pharmacogenetics and Genomics. 28(10). 223–229. 21 indexed citations

15.

Clemens, Eva, Anne-Lotte van der Kooi, Linda Broer, et al.. (2018). The influence of genetic variation on late toxicities in childhood cancer survivors: A review. Critical Reviews in Oncology/Hematology. 126. 154–167. 27 indexed citations

16.

Zolk, Oliver, Bertold Renner, Marios Paulides, et al.. (2013). Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood. 121(26). 5145–5153. 128 indexed citations

17.

Franke, Ryan M., Cynthia S. Lancaster, Kelly K. Filipski, et al.. (2010). Influence of Oct1/Oct2-Deficiency on Cisplatin-Induced Changes in Urinary N -Acetyl-β-D-Glucosaminidase. Clinical Cancer Research. 16(16). 4198–4206. 70 indexed citations

18.

Zolk, Oliver, et al.. (2008). Activation of negative regulators of the hypoxia-inducible factor (HIF) pathway in human end-stage heart failure. Biochemical and Biophysical Research Communications. 376(2). 315–320. 42 indexed citations

19.

König, Jörg, et al.. (2005). ATP-Binding Cassette Transporters in the Heart. Trends in Cardiovascular Medicine. 16(1). 7–15. 47 indexed citations

20.

Castro, Liliana Raquel, Jeanne Mialet‐Perez, Francesca Stillitano, et al.. (2005). Differential functional effects of two 5-HT receptor isoforms in adult cardiomyocytes. Journal of Molecular and Cellular Cardiology. 39(2). 335–344. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact